Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPRX |
---|---|---|
09:32 ET | 30592 | 27.24 |
09:34 ET | 14193 | 27.16 |
09:36 ET | 6300 | 27.2 |
09:38 ET | 9036 | 27.18 |
09:39 ET | 3648 | 27.18 |
09:41 ET | 6636 | 27.24 |
09:43 ET | 11770 | 27.27 |
09:45 ET | 16038 | 27.31 |
09:48 ET | 6595 | 27.295 |
09:50 ET | 3507 | 27.31 |
09:52 ET | 4344 | 27.3 |
09:54 ET | 14432 | 27.23 |
09:56 ET | 2325 | 27.24 |
09:57 ET | 5858 | 27.3 |
09:59 ET | 11470 | 27.31 |
10:01 ET | 19736 | 27.29 |
10:03 ET | 12256 | 27.25 |
10:06 ET | 2811 | 27.275 |
10:08 ET | 3265 | 27.245 |
10:10 ET | 8084 | 27.2 |
10:12 ET | 3131 | 27.23 |
10:14 ET | 115738 | 27.09 |
10:15 ET | 22080 | 27.07 |
10:17 ET | 3269 | 27.11 |
10:19 ET | 5148 | 27.12 |
10:21 ET | 3180 | 27.1101 |
10:24 ET | 24745 | 27.115 |
10:26 ET | 3247 | 27.095 |
10:28 ET | 9683 | 27.035 |
10:30 ET | 4771 | 27.075 |
10:32 ET | 2700 | 27.09 |
10:33 ET | 3825 | 27.11 |
10:35 ET | 5959 | 27.11 |
10:37 ET | 2500 | 27.12 |
10:39 ET | 1834 | 27.16 |
10:42 ET | 1690 | 27.145 |
10:44 ET | 5641 | 27.145 |
10:46 ET | 1720 | 27.14 |
10:48 ET | 3298 | 27.095 |
10:50 ET | 3606 | 27.085 |
10:51 ET | 9649 | 27.105 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Royalty Pharma PLC | 16.3B | 15.2x | +1.83% |
Amneal Pharmaceuticals Inc | 2.1B | -11.7x | --- |
Catalent Inc | 9.9B | -8.5x | --- |
Jazz Pharmaceuticals PLC | 6.7B | 21.5x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Roivant Sciences Ltd | 9.1B | 2.2x | --- |
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.3B |
---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 597.4M |
Dividend Yield | 3.10% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 05-16-24 |
Pay Date | 06-14-24 |
Beta | 0.46 |
EPS | $1.78 |
Book Value | $14.61 |
P/E Ratio | 15.2x |
Price/Sales (TTM) | 7.3 |
Price/Cash Flow (TTM) | 13.7x |
Operating Margin | 41.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.